EMERGENCY:A patient with dermatomyositis who develops rapid-onset breathlessness or falling oxygen saturation —call040-46324365immediately — 24 hours, 7 days— 24/7
Dermatomyositis Treatment in Hyderabad: The Muscle Disease That Shows on the Skin — and the Cancer Screen That Cannot Be Skipped
Expert dermatomyositis diagnosis, systematic skin examination, myositis antibody panel, mandatory malignancy screening, and personalised treatment at KIMS Neuroscience, Secunderabad, Hyderabad.
Dermatomyositis is an autoimmune inflammatory disease affecting both the skin and skeletal muscles, caused by complement-mediated damage to small blood vessels in muscle (microangiopathy) and skin. The defining clinical features are proximal muscle weakness (difficulty rising from chairs, climbing stairs) combined with pathognomonic skin rashes. DM is unique among the inflammatory myopathies in having a visible dermatological calling card. The two most specific skin signs: (1) Heliotrope rash — violaceous (violet-red) discolouration around the upper eyelids, with or without periorbital oedema; (2) Gottron's papules — flat-topped, raised, red-purple papules over the knuckle joints (metacarpophalangeal and interphalangeal). These two signs together are pathognomonic — no other condition produces both. Critical: up to 25% of adult-onset DM patients have an underlying malignancy. Cancer screen is mandatory at diagnosis and annually for 3 years. Myositis-specific antibody (MSA) testing defines the subtype: anti-TIF1-γ (highest malignancy risk, 30-40%), anti-Mi-2 (classic DM, best steroid response), anti-MDA5 (Clinically Amyopathic DM + rapidly progressive ILD, NOT elevated malignancy risk), anti-NXP2 (severe myopathy + calcinosis), others. Treatment: high-dose prednisolone + azathioprine/MTX; hydroxychloroquine for skin; photoprotection mandatory.
- Heliotrope rash + Gottron's papules — pathognomonic together
- Heliotrope rash: violaceous (violet-red) discolouration around the upper eyelids, named after the heliotrope flower. In darker-skinned Indian patients, may appear as subtle darkening or periorbital oedema rather than obvious colour change. Gottron's papules: flat-topped, raised, red-purple papules OVER the knuckle joints (dorsal MCP and IP joints). Key distinction from eczema: Gottron's papules are over the knuckle, visible as textural roughening regardless of skin tone. Eczema affects the web spaces between fingers or flexural surfaces. Together: pathognomonic for DM.
- 7-antibody subtypes — each with different implications
- Anti-TIF1-γ: highest malignancy risk (30-40% of positive adult DM patients have cancer), mandatory aggressive annual malignancy screen for 5 years. Anti-Mi-2: classic DM, best steroid response, lowest malignancy risk, low ILD risk. Anti-MDA5: CADM (skin without muscle weakness) + rapidly progressive ILD (can cause respiratory failure within weeks, NOT elevated malignancy). Anti-NXP2: severe myopathy, calcinosis cutis, malignancy risk. Anti-SAE: dysphagia + malignancy. Anti-Jo-1/antisynthetases: ILD + mechanic's hands + Raynaud's, NOT elevated malignancy. Seronegative: ~30-40% of DM, still requires cancer screen.
- Anti-MDA5 + CADM — the ILD emergency
- Clinically Amyopathic DM (CADM) with anti-MDA5 antibody: skin rashes of DM without muscle weakness or elevated CK. The danger: rapidly progressive interstitial lung disease that can cause respiratory failure within weeks. The absence of muscle weakness falsely reassures clinicians. At KIMS: anti-MDA5 tested in every patient with DM-pattern skin rash, even without muscle weakness. If positive: urgent HRCT chest + DLCO measurement. Oxygen saturation monitoring at every visit. Low threshold for ICU. Tacrolimus or mycophenolate mofetil + high-dose prednisolone from the outset. Rituximab or cyclophosphamide for rapidly progressive ILD not responding to first-line.
- Mandatory cancer screen — the investigation that cannot be skipped
- Up to 25% of adult-onset DM patients have an underlying malignancy — the highest cancer rate of any inflammatory myopathy. The cancer may be occult (no direct symptoms) at the time of DM diagnosis. The KIMS protocol: CT chest/abdomen/pelvis, tumour markers (CA-125, CEA, CA 19-9, AFP, PSA), nasopharyngoscopy (nasopharyngeal carcinoma specifically relevant in South Asian populations), mammography in women, colonoscopy over 50, FDG PET-CT in anti-TIF1-γ positive patients. Annual repeat for 3 years after diagnosis. DM relapse after remission = repeat malignancy screen immediately before attributing to autoimmune flare.
- Dark-skin recognition — specific to the Hyderabad patient population
- The heliotrope rash, named after the heliotrope flower for its violet-purple colour, can be difficult to identify against darker skin tones. In Indian patients: the rash may appear as subtle darkening or discolouration around the eyelids, or primarily as periorbital oedema without obvious colour change. The shawl sign and V-sign may also be less apparent. Gottron's papules, however, are visible as textural roughening and thickening over the knuckle joints regardless of skin tone. At KIMS: full systematic skin examination under adequate lighting, with specific attention to periorbital area (swelling + subtle colour change), knuckles (texture), nailfolds (dilated capillaries), and photodistributed areas.
- Photoprotection as treatment — mandatory in Hyderabad
- Dermatomyositis skin disease is photosensitive: UV radiation directly activates the autoimmune process and can worsen both cutaneous and muscle disease. In Hyderabad's climate, daily UV intensity is high year-round. At KIMS, photoprotection is prescribed as treatment: broad-spectrum SPF 50+ sunscreen (reapplied every 2 hours when outdoors), wide-brimmed hat, UV-protective clothing, avoidance of peak sun hours (10am-4pm). For outdoor workers: UV-protective clothing with UPF rating. Continuing outdoor work without photoprotection while on immunosuppression perpetuates skin inflammation and may trigger muscle flares.
- Hydroxychloroquine — the skin drug in DM
- Hydroxychloroquine (200-400 mg/day) is specifically effective for DM skin manifestations — the heliotrope rash, Gottron's papules, pruritus (itch), and the V/shawl signs. It has anti-inflammatory effects on the DM skin through mechanisms distinct from steroids. Particularly useful for the cutaneous itch that frequently persists despite prednisolone (which controls muscle disease more than skin disease). Slow onset (4-8 weeks for full effect). Well tolerated; requires annual ophthalmology review for retinal toxicity (very rare at standard doses).
About This Condition
Key Facts About Dermatomyositis
The skin signs, who it affects, the malignancy danger, the amyopathic variant, and the dark-skin recognition challenge — at a glance.
What it is
An autoimmune inflammatory disease affecting both the skin and skeletal muscles. Complement-mediated damage to small blood vessels in muscle (microangiopathy) and skin produces the characteristic combination of proximal muscle weakness and pathognomonic skin rashes.
The skin signs
Heliotrope rash — a violaceous (purple-red) discolouration around the eyes. Gottron’s papules — raised, rough, red-purple papules over the knuckles (metacarpophalangeal and interphalangeal joints). These two findings together are the most specific skin signs of dermatomyositis.
Incidence
Annual incidence 0.1–6 per 100,000 population. Female-to-male ratio approximately 2:1. Peak age in adults 50–60 years. Can also affect children (Juvenile Dermatomyositis, where malignancy risk is very low).
The malignancy danger
Up to 25% of adult-onset dermatomyositis patients have an underlying malignancy. This is the highest malignancy rate of all the inflammatory myopathies. The cancer may precede, coincide with, or follow the DM diagnosis. Mandatory cancer screen at diagnosis — no exceptions — at KIMS.
The amyopathic variant
Clinically Amyopathic Dermatomyositis (CADM) — patients have the characteristic skin rashes of DM without muscle weakness or elevated CK. In CADM, interstitial lung disease (from anti-MDA5 antibody) is the life-threatening risk, not muscle failure.
India note
The heliotrope rash can be difficult to identify in darker skin — the violaceous discolouration is subtle against a darker background. At KIMS, the FULL skin examination including scalp, nailfolds, knuckles, and V-chest region is performed in any patient presenting with proximal weakness, as DM-specific skin signs may be present but not immediately apparent.
Emergency
040-46324365
Diagnosis at KIMS
The Diagnosis Written on the Skin
A 54-year-old woman in Hyderabad presents to a dermatologist with a rash around her eyes. The skin over her upper eyelids has turned a subtle purple-red. She also has red, rough papules over the knuckles of both hands. She has been told by a general physician that the eye discolouration is allergic and the hand rash is eczema. She has been using topical steroids on the knuckles for six weeks with no improvement.
When the dermatologist asks whether she has any muscle symptoms, she mentions that she has been struggling to get out of her car for the past two months. She assumed it was her back. Her CK is 2,800 U/L.
At KIMS Neuroscience, the combination is unmistakable: heliotrope rash (the violaceous periorbital discolouration), Gottron’s papules (the raised red-purple papules over the metacarpophalangeal joints — the skin sign that does not occur in eczema, which affects between the knuckles, not over them), and proximal muscle weakness with elevated CK. This is Dermatomyositis. The immediate next steps are a myositis antibody panel, muscle biopsy, CT of the chest, abdomen and pelvis, and tumour markers — because in a 54-year-old woman with adult-onset DM, up to 1 in 4 patients have an underlying malignancy that has not yet been found.
Dermatomyositis is unique among the inflammatory myopathies in having a visible calling card on the skin. The skin signs are pathognomonic — no other condition produces the heliotrope rash and Gottron’s papules together. But they can be missed: in darker-skinned individuals (the majority of patients presenting to KIMS from across Hyderabad, Telangana, and Andhra Pradesh), the violaceous discolouration of the heliotrope rash is genuinely subtle and may be overlooked without systematic skin examination. At KIMS, a full skin survey is performed in every patient with proximal weakness and elevated CK.
Book a Consultation
Speak directly with our dermatomyositis specialist team. No referral required. Monday to Saturday.
040-44885000Emergency line: 040-46324365The Pathognomonic Skin Signs and Other Cutaneous Features
The skin findings of dermatomyositis are among the most specific in all of clinical medicine. Recognising them correctly avoids the months of misdiagnosis that many DM patients experience before reaching a specialist centre.
Heliotrope rash — the eyelid sign
A violet or blue-red discolouration of the upper eyelids, often with periorbital oedema (puffiness around the eyes). Named after the heliotrope flower, whose petals turn towards the sun and match the rash colour. In fair-skinned individuals it is clearly violaceous. In darker skin it may appear as a subtle darkening or discolouration that is easy to dismiss. The swelling component (periorbital oedema) is often more visible than the colour change. Occurs in up to 87% of DM patients.
Gottron’s papules — the knuckle sign
Flat-topped, erythematous to violaceous raised papules over the dorsal surfaces of the metacarpophalangeal (MCP) and interphalangeal (IP) joints — the knuckles. This is the single most specific skin sign in inflammatory myopathy — occurring in DM and not in other conditions. The key distinguishing point from eczema: Gottron’s papules are OVER the knuckle joint; eczema affects the web spaces between fingers. Gottron’s SIGN (a flat, non-papular version) may occur over the elbows and knees.
Shawl sign
A diffuse erythema over the posterior neck, upper back, and shoulders — the area covered by a shawl. It follows a photodistribution, is often pruritic (itchy), and can become poikilodermatous (showing areas of discolouration, scaling, and telangiectasia in longstanding disease).
V-sign
Erythema over the anterior chest and neck in a V-shaped distribution corresponding to sun-exposed skin — the area exposed by a V-neck shirt. Like the shawl sign, it is photodistributed and may be the first cutaneous feature noticed by the patient.
Mechanic’s hands
Roughened, cracked, darkened skin on the lateral and palmar surfaces of the fingers — resembling the hands of a manual worker. This finding is specifically associated with the Antisynthetase Syndrome (anti-Jo-1 and related antibodies) but can also be seen in overlap DM.
Nailfold changes
Dilated, irregular capillary loops at the base of the fingernail (nailfold capillaroscopy — visible with a dermatoscope), ragged cuticles, and periungual erythema. These changes reflect the microangiopathic process that underlies DM. They are also seen in systemic sclerosis.
Calcinosis cutis
Calcium deposits in the skin and subcutaneous tissue, particularly over pressure points (elbows, knees, fingers). More common in Juvenile Dermatomyositis (up to 30–40% of children). Can be painful and restrict movement. No effective pharmacological treatment; surgical removal for symptomatic deposits.
The dark-skin challenge — critical for Indian patients
The heliotrope rash, named after the heliotrope flower for its violet-purple colour, can be difficult to identify against darker skin tones. In Indian patients presenting to KIMS, the rash may appear as subtle darkening or discolouration around the eyelids, or primarily as periorbital oedema without obvious colour change. The shawl sign and V-sign may also be less apparent. Gottron’s papules over the knuckles, however, are typically visible regardless of skin tone as textural changes — roughening and thickening of the skin over the joints. At KIMS, the full skin examination is systematic and includes inspection under adequate lighting with specific attention to the periorbital area, knuckles, nailfolds, and photodistributed areas of the chest and back.
The Antibody Subtypes — Why the Specific Antibody Changes Everything
The myositis-specific antibody (MSA) in a dermatomyositis patient is not just a diagnostic marker. It defines the subtype of DM, predicts the clinical course, identifies the malignancy risk, and guides treatment decisions. At KIMS, antibody testing is performed for every DM patient, and the result directly shapes the management plan.
Anti-TIF1-γ (anti-p155/140)
Clinical associations and implicationsHighest malignancy risk of all DM antibodies — up to 30–40% of anti-TIF1-γ-positive adult DM patients have an underlying cancer. Mandatory aggressive malignancy screen and annual follow-up for 5 years. Classic DM skin findings. Juvenile DM: this antibody is more common in children but does NOT carry the same malignancy risk in that age group.
Anti-NXP2
Clinical associations and implicationsAssociated with severe myopathy, calcinosis cutis (calcium deposits), and dysphagia. Carries a malignancy risk. Interstitial lung disease is NOT typically associated. Needs aggressive myopathy treatment.
Anti-MDA5
Clinical associations and implicationsAssociated with Clinically Amyopathic DM (CADM) — skin rashes without muscle weakness. The critical danger: rapidly progressive interstitial lung disease (ILD) that can cause respiratory failure within weeks. Patients with anti-MDA5 and ILD are a medical emergency at KIMS. Malignancy risk is NOT increased in anti-MDA5 DM.
Anti-Mi-2
Clinical associations and implicationsClassic DM with prominent skin findings. Generally good response to steroids. Best prognosis of the DM-specific antibodies. Low malignancy risk. Low ILD risk.
Anti-SAE
Clinical associations and implicationsAssociated with severe dysphagia and significant malignancy risk. Skin disease can be severe. Less common than other MSAs.
Anti-Jo-1 and other antisynthetases
Clinical associations and implicationsAssociated with Antisynthetase Syndrome: myositis + interstitial lung disease + mechanic’s hands + Raynaud’s phenomenon. Carries ILD risk but NOT elevated malignancy. Specific management for ILD component required.
Seronegative DM
Clinical associations and implicationsApproximately 30–40% of DM patients have no identifiable antibody on standard testing. Management is based on clinical and histological findings. Malignancy screen still mandatory.
The Malignancy Screen — The Investigation That Cannot Be Skipped
Up to 25% of adult-onset dermatomyositis patients have an underlying malignancy. This is the highest cancer rate of any inflammatory myopathy. The cancers most commonly associated with DM include ovarian, lung, gastric, nasopharyngeal, bladder, colorectal, and lymphoma. Anti-TIF1-γ positive patients have the highest malignancy risk.
The cancer may be present at the time of DM diagnosis, may be diagnosed within the first year, or may appear up to 3–5 years later. In some patients, DM is the presenting feature of an occult cancer that has not yet caused direct symptoms. In these cases, successful treatment of the malignancy often results in improvement or complete remission of the DM.
The KIMS structured mandatory protocol
CT chest, abdomen and pelvis — the primary screen for lung, gastric, pancreatic, renal, bladder, and lymphoma
Tumour markers: CA-125 (ovarian), CEA (colorectal and lung), CA 19-9 (pancreatic), AFP, PSA (men)
Nasopharyngoscopy / ENT review — nasopharyngeal carcinoma is specifically relevant in South and Southeast Asian populations including Hyderabad
Mammography and breast ultrasound in women
FDG PET-CT in high-risk patients — anti-TIF1-γ positive patients, older adults, or when CT is inconclusive
Colonoscopy in patients over 50 — colorectal cancer screening as part of the comprehensive workup
Annual review of the malignancy screen for the first 3 years post-diagnosis — and repeated if DM relapses
Relapse of DM after remission — always screen again for malignancy
A relapse of dermatomyositis after a period of sustained remission on treatment is a specific trigger for repeat malignancy screening at KIMS. Cancer-associated DM often relapses in parallel with cancer recurrence. A patient whose DM suddenly worsens after a stable period should be re-screened for the original malignancy and for new primaries before the relapse is attributed solely to autoimmune disease activity.
Amyopathic Dermatomyositis — When the Skin Has the Rash but the Muscle Does Not Have the Weakness
Clinically Amyopathic Dermatomyositis (CADM) is a subset of DM in which patients have the characteristic skin findings of DM — heliotrope rash, Gottron’s papules, and other cutaneous features — without clinically detectable muscle weakness or significantly elevated CK, for a period of at least 6 months. CADM is important for two reasons:
Anti-MDA5 antibody and rapidly progressive ILD
Anti-MDA5-positive CADM carries a risk of rapidly progressive interstitial lung disease that can cause respiratory failure within weeks. The absence of muscle weakness can falsely reassure both the patient and the clinician that the condition is mild. At KIMS, every patient presenting with DM-pattern skin rash — even without muscle weakness — is tested for anti-MDA5. If positive, high-resolution CT of the chest and respiratory function assessment are arranged urgently.
Malignancy risk in CADM
Anti-MDA5-positive CADM does NOT carry an elevated malignancy risk — unlike anti-TIF1-γ positive DM. However, CADM patients who are anti-MDA5-negative or seronegative still require malignancy screening, as the cancer association in DM is not limited to antibody-positive patients.
Aggressive management of anti-MDA5 positive CADM at KIMS
The management of anti-MDA5 positive CADM at KIMS is aggressive from the outset: high-dose prednisolone combined with mycophenolate mofetil or tacrolimus (which has specific evidence in anti-MDA5 ILD), with early escalation to rituximab if the ILD is progressing on first-line therapy. Oxygen saturation monitoring at every visit and low threshold for admission if breathlessness increases.
Diagnosis at KIMS
A structured assessment combining systematic skin examination, muscle enzyme panel, the modern myositis antibody panel, MRI and EMG, expert muscle biopsy interpretation, and mandatory pulmonary assessment — to define the DM subtype, identify the malignancy and ILD risks, and accelerate treatment planning.
Clinical skin examination — systematic and specific
The KIMS skin examination in a suspected DM patient is structured: periorbital skin (heliotrope rash), dorsal hands and knuckles (Gottron’s papules), nailfolds (capillary dilation and ragged cuticles), V-chest area, posterior neck and back (shawl sign), scalp, and lateral thighs (holster sign). In darker-skinned patients, particular attention is paid to textural changes over the knuckles and periorbital oedema rather than colour change alone. Photography of the skin findings at diagnosis provides a baseline for monitoring treatment response.
Serum CK, LDH, aldolase and muscle enzyme panel
CK in DM is typically elevated, usually 5 to 30 times normal in classic DM. In amyopathic DM, CK may be normal or only mildly elevated. Elevated LDH and aldolase support muscle inflammation. AST and ALT may be raised from muscle damage (not liver disease) — a common source of confusion in Indian patients when liver investigations are pursued unnecessarily.
Myositis-specific antibody panel
Anti-TIF1-γ, anti-Mi-2, anti-MDA5, anti-NXP2, anti-SAE, anti-Jo-1, anti-SRP, anti-HMGCR, and ANA. The antibody result defines the DM subtype, predicts the malignancy risk, identifies ILD risk, and guides treatment selection. At KIMS, this panel is sent on the day of first assessment.
Muscle MRI and EMG
MRI of the thighs identifies areas of muscle oedema and inflammation and guides biopsy site selection. EMG confirms the myopathic pattern in patients with muscle weakness and differentiates from neuropathic conditions. In amyopathic DM, EMG may be normal.
Muscle biopsy — the histological signature of DM
The defining histological feature of DM is perifascicular atrophy — a band of small, atrophic muscle fibres at the periphery of muscle fascicles, caused by ischaemia from complement-mediated microangiopathy. C5b-9 (membrane attack complex) deposition on small endomysial blood vessels is also characteristic. These findings are distinct from IMNM (necrotising myopathy). The biopsy is performed at KIMS under local anaesthesia with neuropathological expertise in muscle histochemistry and immunohistochemistry.
Pulmonary assessment — mandatory in all DM
High-resolution CT of the chest and pulmonary function tests (with DLCO — the most sensitive marker of ILD) at diagnosis for all DM patients, not only those with respiratory symptoms. In anti-MDA5-positive patients, this is arranged urgently. Ground-glass changes on CT indicate active ILD that can progress rapidly without treatment.
Treatment
Treatment at KIMS
A three-pronged personalised strategy targeting muscle disease, skin disease, and the anti-MDA5 ILD priority — with concurrent oncology coordination for cancer-associated DM.
Muscle Disease Management
High-dose prednisolone (1 mg/kg/day) is first-line for active muscle disease. In severe disease, IV methylprednisolone pulses (1g/day for 3 days) are used before transitioning to oral. CK and muscle strength are monitored at each visit
Azathioprine or methotrexate are added as steroid-sparing agents. Mycophenolate mofetil is preferred when ILD is present
IVIG for severe acute disease, refractory muscle disease, or pre-surgical management
Rituximab for refractory DM, particularly in anti-Mi-2 and anti-NXP2 positive patients not responding to conventional immunosuppression
Skin Disease Management
Photoprotection — mandatory: Sunscreen (SPF 50+) on all exposed areas, daily, regardless of cloud cover. Protective clothing. Avoidance of peak sun hours. The DM skin rash is photosensitive — UV exposure worsens cutaneous disease and can trigger muscle flares. Indian patients need specific counselling: daily sun exposure (even brief outdoor exposure in Hyderabad’s climate) can perpetuate skin and muscle inflammation
Hydroxychloroquine (200–400 mg/day) — antimalarial with anti-inflammatory properties effective for the skin manifestations of DM. Usually combined with prednisolone. Well tolerated; requires annual ophthalmology review for retinal toxicity
Topical steroids for localised skin flares. Topical calcineurin inhibitors (tacrolimus ointment) for facial and periorbital involvement where topical steroids carry higher side-effect risk
JAK inhibitors (baricitinib, ruxolitinib) — emerging evidence for refractory DM skin disease and ILD. Baricitinib has shown specific benefit for cutaneous DM in prospective studies (2022–2024). Discussed at KIMS for patients with persistently active skin disease despite conventional therapy
ILD Management — The Anti-MDA5 Priority
Anti-MDA5 positive dermatomyositis with interstitial lung disease can progress to respiratory failure within weeks. The ILD protocol at KIMS is structured around urgent imaging, escalating immunotherapy, and a low threshold for ICU admission.
HRCT and PFTs (with DLCO) at diagnosis and every 3–6 months in anti-MDA5 positive patients
Mycophenolate mofetil or tacrolimus — preferred over methotrexate for ILD component
Rituximab — for rapidly progressive ILD not responding to first-line therapy
Cyclophosphamide — used at KIMS for severe, life-threatening rapidly progressive ILD as rescue therapy
Oxygen supplementation and respiratory physiotherapy for patients with established ILD
Low threshold for ICU admission in anti-MDA5 positive patients with any new or worsening breathlessness
Related Conditions
Dermatomyositis sits within the family of idiopathic inflammatory myopathies and related neuromuscular conditions:
FAQs
Frequently Asked Questions
| Fact | Details |
|---|---|
| Pathognomonic signs | Heliotrope rash (violaceous periorbital, subtle in darker skin — look for swelling) + Gottron's papules (OVER knuckles, not between fingers, visible as textural change in darker skin) · Together = pathognomonic |
| 7 antibody subtypes | Anti-TIF1-γ: highest malignancy risk · Anti-Mi-2: classic DM, best steroid response · Anti-MDA5: CADM + ILD emergency, NOT malignancy · Anti-NXP2: calcinosis + malignancy · Anti-Jo-1: ILD but NOT malignancy · Anti-SAE: dysphagia + malignancy · Seronegative: still requires cancer screen |
| Mandatory cancer screen | CT chest/abdomen/pelvis (CT CAP) + tumour markers + nasopharyngoscopy + mammography + colonoscopy >50 · FDG PET-CT for anti-TIF1-γ positive · Annual for 3 years · Relapse = repeat screen immediately |
| Anti-MDA5 emergency | CADM = skin without muscle weakness · Rapidly progressive ILD → respiratory failure within weeks · Urgent HRCT + DLCO · Tacrolimus + MMF + prednisolone · Low threshold for ICU |
| Skin treatment | Photoprotection (SPF 50+) mandatory · Hydroxychloroquine 200-400mg/day for skin + pruritus · Topical tacrolimus (face) · Baricitinib (JAK inhibitor) for refractory cutaneous DM |
| Juvenile DM | Low malignancy risk (vs adult) · High calcinosis risk (30-40%) · Early aggressive treatment reduces calcinosis · MTX as standard steroid-sparing agent |
| Contact | 040-44885000 · Emergency (breathlessness in anti-MDA5 DM): 040-46324365 immediately |
Purple around the eyes. Red rough patches on the knuckles. Weakness getting out of a chair. Three findings that together are a diagnosis — and one that carries a 1-in-4 chance of an underlying cancer in adults. Dermatomyositis needs an expert assessment, not a topical cream.
At KIMS Neuroscience, Secunderabad, Hyderabad, every dermatomyositis patient receives the complete assessment: systematic skin examination including all pathognomonic signs, myositis antibody panel defining the specific subtype, muscle biopsy with neuropathological expertise, high-resolution CT of the chest for ILD, and a structured mandatory malignancy screen. Treatment is personalised: photoprotection and hydroxychloroquine for skin disease, steroids and immunosuppression for muscle disease, anti-MDA5 ILD managed with the urgency it demands, and cancer-associated DM treated with the oncology team simultaneously. At KIMS, a dermatomyositis diagnosis triggers all of this on the same day.
International enquiries: info@kimsneurosciences.com